China Resources Pharmaceutical Group Limited (HKG:3320)

Market Cap	27.77B -6.9%
Revenue (ttm)	314.21B +4.3%
Net Income	4.80B +47.2%
EPS	0.76 +48.4%
Shares Out	6.28B
PE Ratio	5.79
Forward PE	5.61
Dividend	0.23 (5.12%)
Ex-Dividend Date	Sep 10, 2026

Volume	8,526,500
Open	4.530
Previous Close	4.530
Day's Range	4.410 - 4.555
52-Week Range	4.220 - 6.530
Beta	-0.42
Analysts	Buy
Price Target	6.49 (+46.83%)
Est. Earnings	Nov 24, 2026

About HKG:3320

China Resources Pharmaceutical Group Limited, an investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally. It operates through four segments: Pharmaceutical Manufacturing, Pharmaceutical Distribution, Pharmaceutical Retail, and Others. The company offers a range of chemical drugs, Chinese medicines, and biological drugs, as well as nutritional and healthcare products for various therapeutic areas, including cardiovascular, metabolism, i...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2007
• Employees: 84,000
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 3320

Financial Performance

In 2025, HKG:3320's revenue was 269.57 billion, an increase of 4.62% compared to the previous year's 257.67 billion. Earnings were 4.04 billion, an increase of 21.34%.

Financial numbers in CNY

Analyst Summary

According to 11 analysts, the average rating for 3320 stock is "Buy." The 12-month stock price target is $6.49, which is an increase of 46.83% from the latest price.

Price Target

$6.49

(46.83% upside)

Analyst Consensus: Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 22, 2026

Data Sources Report a data error